TTP LabTech and Biostatus Ltd announce compelling data demonstrating the use of DRAQ5 DNA dye in binding assays performed with the Acumen eX3microplate cytometer. In collaborative experiments, DRAQ5 yielded real-time quantitative cell cycle analysis comparable to that obtained using traditional dyes such as Hoechst 34580, DAPI and propidium iodide.
There is an increasing demand for multiplexing in high content assays to maximise data generation and allow correlation across multiple readouts. Currently, there are two areas that present difficulties for the scientist. When fluorescent probes have spectral profiles that overlap, it hinders the degree of multiplexing which can be achieved. The Acumen eX3 offers 405nm, 488nm and 633nm laser excitation in a single instrument, allowing a wider range of fluorescent probes to be used. DRAQ5 is an ideal cell cycle probe since it offers stoichiometric DNA labelling and far-red fluorescent emission when applied to live or fixed cells. When used in multiplex applications with other fluorophores, such as GFP fusions and FITC-tags, there is an exceptional separation between each emission coupled with minimal spectral emission overlap.
This exciting development offers current and future customers improved multiplexing potential. Using DRAQ5 with the Acumen eX3 provides DNA content analysis with fluorescent detection assays across the four detection channels for each laser, giving up to 12 channels for multiplex data. The screening performance of the Acumen eX3 and the spectral properties of DRAQ5 make this a strong combination in multiplexed high content screening.
TTP LabTech’s Chief Scientific Officer, Dr Wayne Bowen welcomed the collaborative progression between the two companies, highlighting “the combination of TTP LabTech’s expertise in fluorescent detection instrumentation and Biostatus’ ability to develop novel reagent technologies creates an excellent opportunity to influence the future of high content multiplex assay analyses.”
Roy Edward, Sales & Marketing Director at Biostatus was delighted at the outcome of this joint effort, adding that “the excellent compatibility of these UK-developed technologies should permit increased information and throughput in fields such as immunology and anti-cancer drug discovery.”
About Biostatus Ltd
Biostatus is focused on cell-based science and its mission is to invent, develop and market novel reagents for use in cell-based research, drug screening and healthcare diagnostics. Biostatus will further expand these markets through the development of complementary detection and screening technologies. Biostatus is committed to providing its customers with highly innovative tools that offer significant advantage to both routine and research-oriented, cell-based analysis. Biostatus’ first product, DRAQ5™ – a unique far-red fluorescing live cell DNA dye, has accelerated and improved cell-based drug discovery assays and expanded the repertoire of available analysis on flow cytometers and fluorescence microscopes.